Previous studies on CIRP as a modulator of inflammation in cancer have revealed that CIRP can act as a damage-associated molecular pattern (DAMP) and stimulate MyD88-NFκB and its subsequent cytokine release via Toll-like receptor 4 (TLR4) binding [23]. This evidence concerns the gene NFKB1 and cancer.